AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against GoodRx Holdings, Inc. (GDRX)

December 28, 2020 GMT

LOS ANGELES--(BUSINESS WIRE)--Dec 28, 2020--

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 16, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX ) Class A common stock between September 23, 2020 and November 16, 2020 inclusive (the “Class Period”).

ADVERTISEMENT

If you suffered a loss on your GoodRx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/goodrx-holdings-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

In September 2020, GoodRx completed its initial public offering (“IPO”), selling over 39.8 million common shares for $33 per share. GoodRx provides consumers with free information and tools to compare prices for prescription drugs. The Company primarily earns revenue from its prescription transaction fees.

On November 17, 2020, Amazon.com, Inc. (“Amazon”) announced two new pharmacy offerings, a Prime Rx plan and a discount card program, that would directly compete with GoodRx’s platform.

On this news, the Company’s stock price fell $10.51, or 23%, to close at $36.21 per share on November 17, 2020, thereby injuring investors.

ADVERTISEMENT

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Amazon had been in the process of developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service; and (2) that Amazon’s services would directly replicate and compete with the GoodRx business model.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired GoodRx Class A common stock during the Class Period, you may move the Court no later than February 16, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com:https://www.businesswire.com/news/home/20201228005015/en/

CONTACT: Glancy Prongay & Murray LLP, Los Angeles

Charles Linehan, 310-201-9150 or 888-773-9224

shareholders@glancylaw.com

www.glancylaw.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: LEGAL PROFESSIONAL SERVICES

SOURCE: Glancy Prongay & Murray LLP

Copyright Business Wire 2020.

PUB: 12/28/2020 12:30 PM/DISC: 12/28/2020 12:30 PM

http://www.businesswire.com/news/home/20201228005015/en